Double-Drug attack on advanced prostate cancer begins human testing
NCT ID NCT06095089
Summary
This early-stage trial is testing a new two-drug combination for men with advanced prostate cancer that has spread. The main goal is to find safe dose levels and check for side effects. Researchers will also look for early signs that the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Leon Berard
RECRUITINGLyon, 69008, France
-
Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
RECRUITINGNew York, New York, 10032, United States
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94800, France
-
South Texas Accelerated Research Therapeutics, LLC (START)
RECRUITINGSan Antonio, Texas, 78229, United States
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
-
University of Colorado Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.